- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09.24 | Enzolytics, Inc.: Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator | 374 | ACCESS Newswire | FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of... ► Artikel lesen | |
| 09.09.24 | Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement | 517 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology,... ► Artikel lesen | |
| 20.08.24 | Enzolytics, Inc.: Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells | 372 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious... ► Artikel lesen | |
| 31.07.24 | Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications | 525 | ACCESS Newswire | As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company... ► Artikel lesen | |
| 29.07.24 | Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd. | 292 | ACCESS Newswire | Updates on Results of Litigation ALLEN, TX / ACCESSWIRE / July 29, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration... ► Artikel lesen | |
| 26.07.24 | Enzolytics, Inc.: Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release | 624 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam... ► Artikel lesen | |
| 01.07.24 | Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment | 355 | ACCESS Newswire | Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide... ► Artikel lesen | |
| 03.06.24 | Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology | 433 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that the Company and Sagaliam Acquisition Corp ("SAGA") are negotiating... ► Artikel lesen | |
| ENZOLYTICS Aktie jetzt für 0€ handeln | |||||
| 22.05.24 | Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation | 422 | ACCESS Newswire | Updates on ETC Marketing, Inc and Ownership of ITV-1 and IPFALLEN, TX / ACCESSWIRE / May 22, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 65,26 | 0,00 % | Morgan Stanley raises Tempus AI price target to $65 from $60 | ||
| QIAGEN | 37,995 | +2,05 % | Biotech Report: Qiagen klettern, Evotec leichter | (shareribs.com) Frankfurt / New York 05.05.2025 - Biotech-Aktien zeigen sich zum Wochenauftakt überwiegend leichter. Nicht nur im deutschen Handel, sondern auch an der Wall Street gibt der Sektor nach.Der... ► Artikel lesen | |
| ARCELLX | 56,26 | 0,00 % | Arcellx, Inc. - 10-Q, Quarterly Report | ||
| TARSUS PHARMACEUTICALS | 47,140 | -0,46 % | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | ||
| ADMA BIOLOGICS | 21,210 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| BIONTECH | 84,70 | +0,36 % | BioNTech-Aktie: Wahnwitzig! | News von Trading-Treff.de BioNTech hat am Freitag einen enormen Aufschlag in Höhe von 1,3 % realisiert. Die Aktie konnte sich damit in den vergangenen fünf Tagen um 5 % nach oben schieben. Der Kurs... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,295 | 0,00 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
| EVOTEC | 6,880 | -2,30 % | BioTech ist zurück mit Künstlicher Intelligenz! Evotec, NetraMark Holdings, Bayer und BioNTech | Die Künstlicher Intelligenz ist in der Gesundheitsforschung angekommen! Immer wenn es um die Auswertung großer Datenmengen, das Erkennen von Mustern oder die Verdichtung von Ergebnissen ankommt, benötigt... ► Artikel lesen | |
| JANUX THERAPEUTICS | 26,370 | +2,61 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| SPRINGWORKS THERAPEUTICS | 46,205 | +0,01 % | Fast vier Milliarden für Healthcare: Wachstum mit Biopharma: Merck übernimmt SpringWorks Therapeutics | ||
| NUVALENT | 71,58 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results | Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission... ► Artikel lesen | |
| NOVAVAX | 5,896 | -0,39 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,395 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,640 | 0,00 % | Summit Therapeutics stock rating upgraded to Buy at TD Cowen | ||
| BEAM THERAPEUTICS | 17,240 | 0,00 % | Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for its first quarter that increased from last year and missed the Street estimates.The company's bottom line totaled -$109.27... ► Artikel lesen |
ENZOLYTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZOLYTICS INC finden Sie auf Wallstreet Online.